Counterfeit Retatrutide: 7th Liver Toxicity Case Prompts Batch Testing

Doctors in Victoria, Australia are testing suspect batches of counterfeit retatrutide after a seventh patient was hospitalized with acute liver toxicity from an unapproved peptide product, prompting fresh warnings from the country’s medicines regulator. The Therapeutic Goods Administration (TGA) says the localized cluster suggests a possible “batch problem” with counterfeit product — the latest real-world evidence of harm from the unregulated peptide gray market, as reported by ABC News.

Seven Cases, One Suspected Source

Liver transplant specialist Marie Sinclair, who has treated liver failure patients in Victoria, said a patient had recently become seriously unwell after a second dose of unregulated retatrutide. “We have seen a recent case again, fairly similar to previous cases, where after a second dose of unregulated retatrutide there was severe liver injury,” Dr. Sinclair told the ABC.

The cluster now stands at seven hospitalized patients in Victoria since January 2026. Dr. Sinclair said she had commissioned testing of counterfeit peptides used by liver failure patients to determine whether a contaminant is responsible. “It’s uncertain as to why this has happened, but one possibility is that there could be a contaminated batch of [counterfeit] retatrutide that is in Victoria,” she said, adding that the explanation remains “purely a hypothesis at this stage” until testing results come back.

TGA: “Not the Retatrutide in Clinical Trials”

Robyn Langham, the TGA’s chief medical advisor, told the ABC the localized nature of the liver injuries “suggested a batch problem” and that black-market retatrutide is a “counterfeit product.” “The retatrutide that’s being sold is not the retatrutide that’s currently in clinical trials,” Professor Langham said, pointing to the Victoria state health alert issued in June that flagged products labelled Retatrutide, Reta, R-10, or R-20.

The TGA’s June media release warned that unapproved peptide products have not been evaluated for safety, quality, or effectiveness, and that injected products carry particular risks including contamination, infection, and “potentially life-threatening reactions.”

Professor Langham said there are “no good batches or safe unapproved peptides.” “There are hospital admissions happening across the country because of the use of unapproved peptides,” she said. “The risks are real, they are not theoretical.”

Canberra Health Services confirmed it had detected liver damage from products sold as retatrutide, though it would not disclose numbers “due to the low numbers involved.”

The Human Cost

ABC News reported the case of Megan Hancocks, who bought a product labelled retatrutide in cash from a beautician and was in acute liver failure within a week of her second dose. Victoria’s health department has advised anyone who has used such products and developed symptoms — tiredness, abdominal pain, dark urine, yellow eyes or skin, easy bruising — to seek medical attention promptly.

Enforcement Escalates

The TGA reported that more than 94,500 unapproved peptide products had been destroyed this year in collaboration with the Australian Border Force. Last week, the TGA and New South Wales Police seized more than $120,000 of “illicit peptide and anabolic steroid products” from premises allegedly linked to social media influencers. In April, authorities seized $2 million worth of steroids and peptides.

The enforcement actions mirror a broader international pattern we tracked in May coverage of the TGA’s warnings and the Lancet’s warning on young Australians, where adolescent use of unapproved peptides has outpaced both regulatory and clinical responses.

What the Manufacturer Says

Eli Lilly, which owns the patent on retatrutide and is running clinical trials for the experimental weight-loss peptide, said any version sold online is not its product. “Lilly continues to warn the public about the potential dangers of fake medicines,” Manny Simons, general manager of Lilly Australia, said in a statement to the ABC. “Any retatrutide available online is unapproved, unverified and simply not worth the risk.”

Why This Matters

Retatrutide is an investigational triple-agonist peptide that has not been approved by any regulator. Products sold under its name in the unregulated market are not the compound being studied in trials, and there is no way for a buyer to verify what they contain — a point Professor Langham stressed when warning that “adolescents, young children are buying these and injecting them into themselves.”

The Victoria cluster is the clearest documented instance to date of serious clinical harm linked to counterfeit peptide products, and the batch-testing investigation now underway could determine whether a single contaminated production run is responsible. For anyone tracking peptide policy, the case is also a preview of the enforcement burden regulators face as demand for these compounds outruns the legal supply chain — a theme that continues to shape the U.S. debate ahead of the FDA compounding enforcement picture and the July PCAC recommendations.

Nothing in this article is medical advice. Retatrutide is an investigational compound; products sold under its name outside clinical trials are unapproved and unverified.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.